New York, New York--(Newsfile Corp. - December 31, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inspire Medical Systems, Inc. (NYSE: INSP) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Inspire Medical caused the company to misrepresent or fail to disclose that: (1) the Inspire V launch was going poorly due to a lack of demand caused by providers holding a significant amount of ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - The lawsuit against Inspire Medical Systems, Inc. alleges that the company made misleading statements regarding the demand and launch of its implantable medical device for obstructive sleep apnea, leading to significant financial losses for investors [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Inspire securities between August 6, 2024, and August 4, 2025 [1]. - Allegations include that the company failed to disclose poor demand for its product and had surplus inventory, which affected the transition to the new treatment [1]. - The lawsuit claims that Inspire Medical did not complete essential tasks for a successful product launch, contrary to their public assurances [1]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced that the launch of Inspire V was delayed due to incomplete training and onboarding at treatment centers [2]. - The company admitted that software updates necessary for billing were not effective until July 1, leading many centers to continue using an earlier version of the product [2]. - Following the announcement, Inspire's stock price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 per share [2].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would be met once inventory was available [5]. - Contrary to these assurances, Inspire failed to adequately prepare clinicians and payors, leading to delays in adoption and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- National investor rights law firm Hagens Berman alerts INSP investors to the pending securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP). The firm is urging INSP investors who suffered substantial losses to contact attorneys before the January 5, 2026, Lead Plaintiff Deadline. The lawsuit, which is currently pending in the U.S. District Court for the District of Minnesota, alleges that Inspire Medical and its executives misled i ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of misleading statements regarding the launch of its Inspire V device, which has faced significant setbacks and resulted in a substantial drop in stock price [2][4][6]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Inspire Medical to contact them to discuss their legal options [1]. - The firm is reminding investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [2]. Group 2: Company Performance and Issues - Inspire Medical announced on August 4, 2025, that the launch of its Inspire V device faced significant delays due to treatment centers not completing necessary training and onboarding [5]. - The company also reported billing and reimbursement challenges, stating that while Medicare approved a CPT code for Inspire V, software updates for claims processing were not effective until July 1, 2025, leading to continued use of the older Inspire IV system [5]. - Inspire Medical's launch of Inspire V has been affected by weak demand and excess inventory, resulting in a more than 80% cut in its 2025 earnings guidance [6]. - Following these issues, Inspire Medical's stock price plummeted over 32% in one day, from $129.95 to $87.91, erasing approximately $1.2 billion in market capitalization [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

MINNEAPOLIS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Inspire is scheduled to present at 12:45 p.m. Eastern Time. The presentation will be accessible via a live web ...